Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

Abstract Background The ZOHé study was a prospective, non-interventional, multicentre study in France to assess the use of biosimilar filgrastim Zarzio® (Sandoz filgrastim) in routine clinical practice in patients at risk of neutropenia-inducing chemotherapy (CT). Methods Patients ≥ 18 years undergo...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Henri Roché, Jean-Christophe Eymard, Abderraouf Radji, Alain Prevost, Rafik Diab, Michele Lamuraglia, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Alain Toledano
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2018-11-01
coleção:	BMC Cancer
Assuntos:	Biosimilar pharmaceuticals Filgrastim Febrile neutropenia Real-world Chemotherapy Solid tumours
Acesso em linha:	http://link.springer.com/article/10.1186/s12885-018-4986-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!